Sun Pharma shares drop 2% on USFDA warning letter
The USFDA has issued a letter for violations of Current Good Manufacturing Practice (cGMP) regulations at Sun Pharma’s Dadra facility.
sun pharmaceuticals fortune500 snapshot 4
June 2024
September 2023
May 2023
September 2022
June 2022
May 2022
March 2022
February 2022
December 2021
Serum Institute’s Poonawalla richest in Pharma
Cyrus Soli Poonawalla has seen the sharpest increase in wealth in value terms across sectors during the year.
US FDA halts Sun Pharma’s trial on dermatological drugs; stock down
The federal agency has put on hold the trial of 12 mg of Deuruxolitinib clinical trial owing to a potential pulmonary embolism.
Covid catapults Cyrus Poonawalla to richest in pharma
Cyrus Soli Poonawalla’s Serum Institute of India made the most of the country’s demand for vaccines.
Sensex, Nifty to open lower; Vedanta, NTPC, Adani Transmission, Sun Pharma shares eyed
The Sensex and Nifty are poised to start the week on a negative note, tracking weak cues from global peers and bearish trading on the SGX Nifty futures.
Lawsuit settlements drag Sun Pharma into ₹2,227 cr loss in Q4
Sun Pharma incurred an exceptional loss of ₹3,936 crore on account of settlements, provisions related to Taro Pharmaceuticals, Ranbaxy.
Why are Sun Pharma, Zenotech Lab shares trading higher today?
Shares of Sun Pharmaceutical Industries climbed nearly 1% in opening trade, while Zenotech Laboratories was locked in an upper circuit of 5% on the BSE.
Soft opening seen for Sensex, Nifty; Airtel, RIL, Future Retail, Sun Pharma shares in focus
The BSE Sensex and the NSE Nifty are set to start the week on a bearish note, following soft cues from Asian peers and negative trade at SGX Nifty.
D-Street thumbs up for Budget 2022; Sensex soars 848 pts, Nifty reclaims 17,500
This was the third-best performance by the domestic bourses on a Budget day in the last ten years, with Sensex surging 1.46% to 58,862 points.
Sensex, Nifty to see gap-down opening; Raymond, Sun Pharma, ITC, AU Small Finance Bank in focus
Dalal Street headed for a negative start on Wednesday, following weak cues from Asian peers as market participants remained concerned about the Omicron variant of Covid-19.
